There Is Progress At PAVmed, But More Patience Is Required
The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage.
Yet, like for most pre-revenue medical device companies, the pandemic has complicated things quite a lot and by the looks of it, might well do so again.
We still like the company longer-term though but this is one to slowly accumulate on dips, there are likely to be some of these left.
This idea was discussed in more depth with members of my private investing community, SHU Growth Portfolio. Get started today »